DermaClinic - Company finances
|
EUR
|
2022
From: 2022-06-09
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 220 | 22,452 | 214,271 | 319,146 |
| Profit before tax | -7,571 | -35,542 | - | - |
| Net profit | -7,571 | -35,542 | -26,897 | 4,594 |
| Equity | -5,071 | -40,613 | -67,510 | -62,916 |
| Liabilities | 74,248 | 267,813 | 296,601 | 258,814 |
| Non-current assets | 57,987 | 192,847 | 188,984 | 184,719 |
| Current assets | 11,164 | 34,353 | 40,107 | 11,102 |
| Total assets | 69,151 | 227,200 | 229,091 | 195,821 |
|
Taxes paid
|
||||
| STI taxes | - | 245 | 7,656 | 10,344 |
| Social insurance contributions | - | 2,872 | 12,507 | 16,352 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +10105.5% | +854.4% | +48.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -10.9% | -15.6% | -11.7% | 2.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -3441.4% | -158.3% | -12.6% | 1.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -3441.4% | -158.3% | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 189 | 4,645 | 21,427 | 22,661 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
DermaClinic - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-06-11 | 2026-06-11 | 0.01 |
| 2026-05-17 | 2026-06-08 | 0.01 |
| 2025-05-04 | 2025-05-06 | 0.42 |
| 2025-04-24 | 2025-04-29 | 0.42 |
| 2025-03-03 | 2025-03-03 | 142.87 |
| 2025-02-18 | 2025-02-27 | 142.87 |
| 2023-06-16 | 2023-06-25 | 77.09 |
| 2023-05-16 | 2023-05-22 | 290.18 |
DermaClinic - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-09-14 | 2026-09-14 | 0.0 |
| 2026-09-02 | 2026-09-13 | 1.66 |
| 2026-08-31 | 2026-09-01 | 1.66 |
| 2026-08-30 | 2026-08-30 | 4.54 |
| 2026-08-28 | 2026-08-29 | 4.54 |
| 2026-08-26 | 2026-08-27 | 0.0 |
| 2026-08-25 | 2026-08-25 | 0.0 |
| 2026-08-23 | 2026-08-24 | 0.0 |
| 2026-08-20 | 2026-08-22 | 4.54 |
| 2026-08-19 | 2026-08-19 | 4.54 |
| 2026-08-18 | 2026-08-18 | 4.54 |
| 2026-08-17 | 2026-08-17 | 4.54 |
| 2026-08-13 | 2026-08-16 | 4.54 |
| 2026-08-12 | 2026-08-12 | 4.54 |
| 2026-08-10 | 2026-08-11 | 4.54 |
| 2026-08-09 | 2026-08-09 | 4.54 |
| 2026-08-07 | 2026-08-08 | 4.54 |
| 2026-08-06 | 2026-08-06 | 4.54 |
| 2026-08-05 | 2026-08-05 | 4.54 |
| 2026-08-03 | 2026-08-04 | 4.54 |
| 2026-07-26 | 2026-08-02 | 0.0 |
| 2026-07-07 | 2026-07-25 | 19743.45 |
| 2026-07-06 | 2026-07-06 | 19743.45 |
| 2026-06-29 | 2026-07-05 | 19743.45 |
| 2026-06-03 | 2026-06-28 | 20755.54 |
| 2026-06-02 | 2026-06-02 | 20755.52 |
| 2026-06-01 | 2026-06-01 | 20987.52 |
| 2026-05-31 | 2026-05-31 | 20986.9 |
| 2026-05-30 | 2026-05-30 | 20836.68 |
| 2026-05-28 | 2026-05-29 | 20743.27 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
DermaClinic, UAB (code 306098278) is a Private Limited Liability Company active in other human health activities n.e.c. In 2025, the company generated revenue of €319.1K, up 49.0% year on year and 1321.5% over two years. After losses of €35.5K in 2023 and €26.9K in 2024, net profit turned positive at €4.6K in 2025, with a profit margin of 1.4%. The turnaround came alongside a mixed balance sheet picture: total assets fell to €195.8K from €229.1K in 2024, while equity remained negative at €62.9K and liabilities were €258.8K. Long-term assets were €184.7K and short-term assets €11.1K. Return metrics were modest, with ROA at 2.4% and ROE at -7.3%, which should be interpreted in light of negative equity. Asset turnover was 1.63x. Revenue per employee was €22.8K and profit per employee €328, indicating improved trading performance but still a constrained capital structure.